Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Fineline Cube Jan 12, 2026
Company Deals

Mirxes Partners with Thailand’s N Health to Launch miRNA Cancer Screening

Fineline Cube Jan 12, 2026
Company Deals

Biocytogen Licenses ADC Programs to Acepodia in Option Deal

Fineline Cube Jan 12, 2026
Company Deals

Simcere Pharma to Spin Off Zaiming Unit for Hong Kong IPO

Fineline Cube Jan 12, 2026
Company Deals

Nona Biosciences Partners with Link Cell on CAR-T Discovery Using HCAb Platform

Fineline Cube Jan 12, 2026
Company Drug Policy / Regulatory

FDA Announces Flexible CMC Pathway for Cell and Gene Therapies to Accelerate Development

Fineline Cube Jan 12, 2026
Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Fineline Cube Jan 12, 2026
Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Fineline Cube Jan 12, 2026
Company Deals Digital

Zhejiang Dian Diagnostics Partners with Meituan for Digital Healthcare Services Expansion

Fineline Cube Apr 14, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a prominent medical diagnostics company based in China,...

Company Drug

Ocumension Therapeutics’ Zerviate NDA Accepted for Review by China’s NMPA

Fineline Cube Apr 14, 2023

Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that the National Medical...

Company Deals

Pfizer and Sinopharm Expand Partnership to Enhance Drug Distribution and Lifecycle Solutions

Fineline Cube Apr 14, 2023

US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced a strategic partnership with China-based Sinopharm...

Company Drug

Fosun Pharmaceutical’s FCN-159 Earns Breakthrough Therapy Designation for Histiocyte Tumors

Fineline Cube Apr 14, 2023

The Center for Drug Evaluation (CDE) website has announced that Shanghai Fosun Pharmaceutical (Group) Co.,...

Company Drug

Aosaikang Pharmaceutical Receives NMPA Review for ASKC200 Liniment from Propella Therapeutics

Fineline Cube Apr 14, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the National Medical Products Administration...

Company R&D

HuidaGene Therapeutics Enhances CRISPR-Cas12f System with Higher Editing Efficiency

Fineline Cube Apr 14, 2023

HuidaGene (Shanghai) Therapeutics Co., Ltd, a China-based biotechnology company, has made significant strides in the...

Company Deals

Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion

Fineline Cube Apr 14, 2023

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed...

Company

Huadong Medicine Reports 9.12% YOY Revenue Growth and 13.24% Increase in Net Profits for 2022

Fineline Cube Apr 14, 2023

Huadong Medicine Co., Ltd (SHE: 000963), a leading China-based pharmaceutical company, has released its 2022...

Company

BeiGene Launches LATAM Expansion with New Office in São Paulo, Brazil

Fineline Cube Apr 14, 2023

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235), a China-based biopharmaceutical company, has announced its first...

Company R&D

Diapin Therapeutics Announces Breakthrough Preclinical Results for DT-109 in NASH Treatment

Fineline Cube Apr 13, 2023

US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its...

Company Drug

Convalife Pharmaceuticals’ Mefuparib Earns Orphan Drug Designation for Cholangiocarcinoma

Fineline Cube Apr 13, 2023

Shanghai-based Convalife Pharmaceuticals has announced that it has received orphan drug designation (ODD) status from...

Company Deals

VintaBio Secures $64M Funding to Revolutionize Viral Vectors for Cell and Gene Therapy

Fineline Cube Apr 13, 2023

New biotech VintaBio, founded in Philadelphia, Pennsylvania (United States), announces the appointment of CEO David...

Company Deals

Alebund Pharmaceuticals Secures $29M in Pre-Series C Funding and $116M Loan for R&D and Manufacturing

Fineline Cube Apr 13, 2023

Shanghai-based Alebund Pharmaceuticals has announced the completion of a pre-Series C financing round worth RMB...

Company Drug

Overland ADCT BioPharma Achieves Primary Endpoint in Zynlonta Phase II Study for R/R DLBCL

Fineline Cube Apr 13, 2023

Joint venture Overland ADCT BioPharma (CY) Ltd, a partnership between China’s Overland Pharmaceuticals and Swiss...

Company Drug

Novartis’ Jakavi Secures NMPA Approval for Acute GVHD Treatment in China

Fineline Cube Apr 13, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that it has received a new indication...

Company Drug

Chengdu Hyperway Pharmaceuticals’ HBW-004285 Gets NMPA Tacit Approval for Pain Treatment

Fineline Cube Apr 13, 2023

China-based Chengdu Hyperway Pharmaceuticals has announced receiving tacit clinical trial approval from the National Medical...

Company Medical Device

Shanghai Bio-Heart’s Iberis RDN System Meets Primary Endpoint in Iberis-HTN Study

Fineline Cube Apr 12, 2023

Shanghai Bio-Heart Biological Technology Co., Ltd (HKG: 2185) has announced that its Iberis multi-electrode renal...

Company Drug

Grand Pharmaceutical’s APP13007 Achieves Clinical Endpoints in US Trials for Post-Operative Treatment

Fineline Cube Apr 12, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that a Phase II clinical study...

Company Drug

Sirnaomics Commences Phase I Clinical Trial for Factor Xl RNAi Drug STP122G

Fineline Cube Apr 12, 2023

Sirnaomics Ltd (HKG: 2257) has announced the commencement of a single-center, randomized, double-blind, placebo-controlled, sequence...

Company Drug

Shanghai Fosun Pharmaceutical Submits Market Approval Filing for Daxibotulinumtoxin A in China

Fineline Cube Apr 12, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a market approval filing to...

Posts pagination

1 … 479 480 481 … 607

Recent updates

  • Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC
  • Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1
  • Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer
  • Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease
  • Lynk Pharmaceuticals Reports Positive Phase III Data for Zemprocitinib in Rheumatoid Arthritis – Best‑in‑Class JAK1 Inhibitor Shows 79 % ACR20 Response
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Noetik Enters $50M AI Collaboration with GSK, Licensing OCTO‑VC Virtual Cell Models for NSCLC and CRC

Company Drug

Alphamab Oncology Submits Envafolimab for First‑Line Biliary Tract Cancer (BTC) as World’s First Subcutaneous PD‑L1

Company Drug

Pfizer’s BRAFTOVI Trio Achieves 64 % Response Rate in BREAKWATER Cohort 3 for BRAF V600E Metastatic Colorectal Cancer

Company Drug

Insilico Medicine Doses First Patient in Phase IIa Study of AI‑Designed ISM5411 for Inflammatory Bowel Disease

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.